Open Demo Account
Home / Market Update / Gilead Sciences: We’ll Be Able to Make Enough Remdesivir in October

Gilead Sciences: We’ll Be Able to Make Enough Remdesivir in October

Adel 7 August, 2020 1:17 pm Market Update

Biotech company Gilead Sciences said it will be able to produce enough anti-coronavirus drug Remdesivir to meet global demand in October.

In addition, Gilead said it plans to produce more than 2 million “treatment courses” for the drug by the end of the year, and expects to be able to produce “several million more” in 2021.

The company also added that it has increased the supply of the drug more than 50-fold since January.

Tags

Check Also

NFP

NFP Preview: What to Expect? Why do Investors Focus on Powell’s Speech?

The looming U.S. Non-Farm Payrolls (NFP) report on Friday has garnered a significant amount of …

This site contains information and opinions for the purpose of providing only general information and can not be relied upon. The information and opinions contained in this Site shall in no way constitute an offer or solicitation to buy, sell or subscribe to any investment product. Users of this site shall bear any risks arising from the use of any information, opinion, program, service or material. Noor Trends reserves the right to make any change to the Site, the information, opinions, materials, products, programs, services or prices (if any) at any time without notice.
All copyrights reserved Noor Trends